Stay updated on Ascending Dose Study of ZFN Therapeutic SB-913 in MPS II Clinical Trial
Sign up to get notified when there's something new on the Ascending Dose Study of ZFN Therapeutic SB-913 in MPS II Clinical Trial page.

Latest updates to the Ascending Dose Study of ZFN Therapeutic SB-913 in MPS II Clinical Trial page
- Check6 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4. No substantive study information or documents were changed.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedLocations sections were reorganized: a main Locations section added with state subheadings (California, Illinois, New York, North Carolina, Ohio) and the prior state-specific sections removed; the page revision notes show an update from v3.3.2 to v3.3.3.SummaryDifference0.6%

- Check56 days agoChange DetectedPublication note now states that PubMed entries are automatically filled and may not pertain to the study, and the revision tag has been updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check63 days agoChange DetectedThe site-wide funding-status notice near the top of the page has been removed. The study details and related information remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check77 days agoChange DetectedThe Study Details page shows only minor visual/layout changes with no updates to core content such as eligibility criteria, endpoints, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check106 days agoChange Detected- Added a prominent notice about potential outages due to lapse in government funding and updated operating status guidance. - Updated version from v3.1.0 to v3.2.0.SummaryDifference4%

Stay in the know with updates to Ascending Dose Study of ZFN Therapeutic SB-913 in MPS II Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ascending Dose Study of ZFN Therapeutic SB-913 in MPS II Clinical Trial page.